Financial Engines Advisors
GNOM icon

Financial Engines Advisors’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Financial Engines Advisors’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,375
Closed -$383K – 308
2022
Q1 		$383K Sell
6,375
-117
-2% -$7.38K ﹤0.01% 224
2021
Q4 		$516K Buy
6,492
+3,608
+125% +$303K ﹤0.01% 155
2021
Q3 		$255K Buy
+2,884
New +$270K ﹤0.01% 237

Other funds holding GNOM

Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
MIG
McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return
OCM
One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return

Financial Engines Advisors's GNOM Position: Q2 2022 in Review

Financial Engines Advisors sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q2 2022, closing a stake of 6,375 shares — an estimated $383K sold.

Financial Engines Advisors first reported a position in GNOM in Q3 2021 and held it in 3 quarters. The position peaked at $516K in Q4 2021. 58 funds tracked by Wall St. Rank hold GNOM as of Q2 2022.

  • Financial Engines Advisors reported no remaining Global X Genomics & Biotechnology ETF position as of Q2 2022 after selling out during the quarter.
  • Financial Engines Advisors sold 6,375 Global X Genomics & Biotechnology ETF shares in Q2 2022, an estimated $383K.
  • Financial Engines Advisors first reported a position in Global X Genomics & Biotechnology ETF in Q3 2021 and held it in 3 quarters.
  • Financial Engines Advisors's Global X Genomics & Biotechnology ETF position peaked at $516K in Q4 2021.
  • 58 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q2 2022.

Based on Financial Engines Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.